Eurpean Ad Comm recommends Gazyvaro

The EU Committee for Medicinal Products for Human Use recommends that the EC approve Roche's (RHHBY) Gazyvaro (obinutuzumab) in combination with chlorambucil for the treatment of adults with chronic lymphocytic leukemia (CLL) who have comorbidities making them unsuitable for full-dose fludarabine.

In a Phase 3 trial Gazyvaro plus chlorambucil reduced the risk of disease worsening or death by 86% and increased survival time in untreated CLL patients who received chlorambucil alone.

The EC's full decision should occur in the next several months. The product is already approved in the U.S. and rest of the world.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs